Abstract Machado-Joseph disease (MJD) is a late-onset autosomal dominant neurodegenerative disorder, which is caused by a coding (CAG) n expansion in the ATXN3 gene (14q32.1). The number of CAG repeats in the expanded alleles accounts only for 50 to 75 % of onset variance, the remaining variation being dependent on other factors. Differential allelic expression of ATXN3 could contribute to the explanation of different ages at onset in patients displaying C. Bettencourt : N. Kazachkova : J. Sequeiros : J. Bruges-Armas :
Introduction
Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (OMIM #109150) is an autosomal dominant neurodegenerative disorder. Most patients show the first symptoms in adulthood (mean~40 years), but onset extremes of 4 and 70 years have been described [1, 2] . The MJD phenotype is complex and pleomorphic, involving the cerebellar, ocular motor, pyramidal, extrapyramidal, and peripheral motor systems, at variable degrees [2] .
MJD's causative mutation corresponds to an expansion of a (CAG) n motif in exon 10 of the ATXN3 gene (14q32.1) [3, 4] . Normal alleles range from 12 to 44 CAG repeats, while expanded alleles present more than 52 repeats [5, 6] . The size of the expanded tract is incompletely correlated with the age at onset, explaining from 50 to 75 % of its variance [7, 8] . Other factors (genetic, environmental, or both) should contribute to the clinical variability observed; to date, only the APOE gene has been established as a modifier of the age at onset in MJD [9] , while GRIK2, IL1B, and NEDD8 genes have been suggested as possible modifiers [10] .
The ATXN3 gene encodes for ataxin-3, which displays distinct isoforms [11] , and presents, in its mutated form, an abnormal elongation of the polyglutamine tract near its Cterminus [3] . This gene is ubiquitously expressed, in neuronal and non-neuronal tissues, thus the presence of the mutated gene cannot explain by itself the selective neuronal degeneration observed in MJD (reviewed in [6] ). The idea that the levels of expression of the mutant allele may contribute to neurodegeneration has been supported by observations from modelbased studies [12, 13] , as well as by the earlier onset and faster progression of the disease seen in homozygous patients [1, 14, 15] . Therefore, we can hypothesize that higher expression levels of mutant ataxin-3 in heterozygous patients may also be associated with a more severe phenotype, namely with a decrease in age at onset.
Variation in noncoding regulatory regions, i.e., those at 5′, may affect gene expression levels in an allele-specific manner [16] . Besides the promoter, gene expression levels may be further influenced by cis-regulatory elements located in the 5′ untranslated region (UTR) [17] . The ATXN3 promoter has been described as being directly upstream of the gene. Its core region of transcriptional activation, containing consensus sequences for a CCAAT box and SP1 binding sites, appears to be located between −291 and the transcription start site [18] . Although the genomic structure of the ATXN3 5′ flanking region has already been described, the extent of variation in this region, which could be involved in transcriptional and translational regulation, remains unexplored.
The main goal of this work was to describe the variation upstream of the ATXN3 gene start codon, in its core promoter and 5′ UTR, in MJD patients and in controls. Furthermore, this work aimed to investigate potential modulating effects of such putative variation on the age at onset of MJD.
Patients and Methods

Subjects
After informed consent, blood samples were collected from 186 MJD patients (59 from the Azores, 67 from mainland Portugal, and 60 from Brazil) and 59 apparently healthy Caucasian controls (molecularly excluded for the CAG expansion). DNA was extracted from whole blood using standard procedures. The age at onset was available for the series of MJD patients in the study, and it was defined as the age at which the first complaints of gait instability or diplopia were noticed (more details in [9] ). The (CAG) n tract size in ATXN3 gene was also available, and had been determined according to Bettencourt et al. [19] .
Amplification and Sequencing
A fragment of 816 bp, containing the core promoter and the 5′ UTR ( Fig. 1) , as well as downstream sequences of the ATXN3 gene, was amplified using the following set of primers: P-1aF (5′-CAAGTGCTGGGTTTTGGGAG-3′) and P-1R (5′-AAAGCGATGGAAAGTGACGG-3′). An initial denaturation step (95°C, 5 min) was followed by 37 cycles of denaturation (94°C, 30 s), annealing (56°C, 30 s), and extension (72°C, 45 s), and a last step of extension (72°C, 7 min). PCR products were purified using a Spin Kit (Genomed). All samples were sequenced in both forward and reverse directions, using primers P-1aF and P-1aR (5′-ACGCGGACACTCACTTTCTC-3′), and whenever necessary using P-1R. Sequence reactions were carried out using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and run in an ABI 310 sequencer. All sequence alignments, namely of the obtained sequences with the Homo sapiens genomic DNA sequence (GenBank AB038653.1), were performed with BioEdit v7.0.9.0 [20] .
In Silico Sequence Analysis Two predicting tools, TFBIND (http://tfbind.ims.u-tokyo.ac. jp) [21] , and MATCH™ (http://www.gene-regulation.com/ pub/programs.html#match) [22] , were used to find differences in putative transcription factor (TF) binding sites due to rs3814834.
Statistical Analysis
Genotypic and allelic frequencies of rs3814834 were determined. Conformity with the Hardy-Weinberg equilibrium expectations was tested. An exact test of differentiation evaluated differences in genotypic frequencies for this SNP between patients and controls. Analyses were performed using the Arlequin software v.3.1 [23] , with a level of significance of 0.05. OpenEpi v.2 proportion calculator (www.openepi.com) was used to determine the 95 % confidence intervals for the allele frequencies present in the Reference SNP Cluster Report of rs3814834 (available at http://www.ncbi.nlm.nih.gov), for the European population (EGP_CEPH-PANEL).
Linear regression analyses were used to test the effect of several variables on age at onset of MJD patients. The multivariate linear model included the following covariates: CAG number in expanded and in normal alleles, genotypes for rs3814834, geographical origin, and gender of the patient. Age at onset, stratified by rs3814834 genotypes, was adjusted for the mean number of CAGs in the expanded ATXN3 allele, after fitting a linear regression model. Regression analyses were performed using SPSS v.15.0 [24] . Fig. 1 Diagram representing the genomic region containing the ATXN3 gene (grey boxes representing the coding exons, and white boxes the UTRs), with illustration of the analyzed 5′ regulatory regions, including a portion of the promoter (with the core promoter underlined in blue, from −59 to −291) and the 5′ UTR (with the rs3814834 at −31, and the binding site for CMYB underlined in red). Indications of the start codon (+1 start), and the (CAG) n tract location are also given
Results
Sequence analysis of 420 bp of the ATXN3 gene promoter failed to reveal any polymorphism in this region (N0490 chromosomes). At the 5′ UTR, a previously described polymorphism, c.−31C>T (rs3814834), was observed (Fig. 1) , in both patients and controls. Genotypic frequencies (Table 1) were in conformity with Hardy-Weinberg expectations. In control samples, all three possible genotypes (C/C, C/T, and T/T) were observed (Table 1) . However, in MJD samples, the T/T genotype was absent (Table 1) , resulting in statistically significant differences in genotypic frequencies between patients and controls (p00.00355). Nevertheless, allelic frequencies of 97.7 % (CI 95 % 092.7-99.6) for the C variant, and of 2.3 % (CI 95 % 00. 4-7. 3) for the T variant, are reported for the European population (EGP_CEPH-PANEL), being similar to those obtained for the MJD patients.
For the studied series of patients, a summary of descriptive statistics is shown in Table 2 . Although patients with the C/T genotype (rs3814834) presented an earlier mean age at onset than those with the C/C genotype, such difference disappeared after adjusting the age at onset for the (CAG) n size ( Table 2 ). The expected negative correlation between the size of the (CAG) n tract in the expanded alleles and the age at onset was confirmed in this MJD series (r0−0.773, p< 0.001), explaining by itself 59.5 % of onset variance. In relation to the linear model accounting only for the CAG repeat size in expanded alleles, the multivariate model improved the predictability of the age at onset in about 5.4 % (accounting now for 64.9 % of onset variance). This model counted with significant contributions from the geographical origin (p<0.001) and gender of the patients (p00.005), with male patients presenting earlier ages at onset. Both the (CAG) n tract size in the normal alleles as well as the allelic state of rs3814834 showed no significant effects.
In silico analysis showed that the rs3814834 falls within the recognition site for the binding of CMYB. However, it lies in a nonconserved position for CMYB binding, not altering the binding of this TF.
Discussion
The absence of polymorphisms in the 490 analyzed chromosomes supports the idea of a conserved ATXN3 promoter. This is in agreement with what was previously obtained by Costa et al. [25] , who analyzed the atxn3 promoter in mice and found it to be highly conserved even between species. In the 5′ UTR, the variation found does not seem to alter the putative binding of CMYB, thus no functional effect can be predicted for this variant. Results from in silico analysis are in agreement with the absence of improvement of the linear model when adding the allelic state for the detected SNP (rs3814834). The use of age at onset as the only available measure of phenotype severity constitutes a limitation of our study, given its approximate nature, and especially because variants in regulatory regions may be associated with the disease course (in terms of progression rate and severity, for example), but not with the disease onset.
Supporting our rationale about the effect of variants in 5′ regulatory regions, several studies have reported that variants in these regions of certain genes can be associated with the onset of neurodegenerative diseases, as is the case of Alzheimer's disease (e.g., [26] ) or Parkinson's disease (e.g., [27] ). Similarly to our results, polymorphisms in the 5′ regulatory regions of the HTT gene have not been significantly associated with the age at onset of Huntington's disease (HD) [28] . Nevertheless, contributions of other variants, further upstream of the analyzed regions or even in other regulatory regions (e.g., 3′ UTR), to differential allelic expression of the ATXN3 gene, have not been a matter of study.
Although it was out of the scope of this paper, results from the regression analysis suggested that geographical origin (reflecting environmental and/or other population specific factors) as well as gender of the patients (suggesting the existence of sex-linked factors) may be modulating the toxic effect of the polyglutamine expansion in this series of patients. Several examples of environmental and/or sex-linked factors have been reported for other polyglutamine diseases, such as HD (e.g., [29] [30] [31] ). Specific analyses concerning the effect of such factors in MJD warrant further investigation in future studies.
Summary
In this first report on the extent of genetic variation upstream of the ATXN3 start codon in MJD patients and controls, the core promoter region was shown to be highly conserved. Although the present series of patients previously enabled the detection of a modifier effect of APOE ε2, it was not possible to demonstrate an impact on disease onset related to the SNP (rs3814834) found in the 5′ UTR.
